OTC Markets OTCPK - Delayed Quote USD
Livzon Pharmaceutical Group Inc. (LVZPF)
3.4300
0.0000
(0.00%)
At close: May 13 at 4:00:00 PM EDT
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
11,750,071.9403
11,812,338.8547
12,430,038.3258
12,629,579.0477
12,063,863.2730
Cost of Revenue
4,049,948.2307
4,081,106.9569
4,465,473.3611
4,461,283.0761
4,253,087.4844
Gross Profit
7,700,123.7096
7,731,231.8978
7,964,564.9647
8,168,295.9716
7,810,775.7885
Operating Expense
4,752,707.0646
4,901,107.7210
5,533,852.9054
5,933,892.2358
5,623,144.4947
Operating Income
2,947,416.6450
2,830,124.1768
2,430,712.0593
2,234,403.7358
2,187,631.2938
Net Non Operating Interest Income Expense
156,477.6431
154,945.5978
261,270.2564
212,078.9190
74,323.0827
Pretax Income
2,920,294.7533
2,806,146.2676
2,382,666.5463
2,330,550.6102
2,245,688.8298
Tax Provision
528,246.7755
501,661.3151
485,065.5340
374,973.2276
293,587.6608
Net Income Common Stockholders
2,089,979.9261
2,061,095.8040
1,953,650.8333
1,909,407.6879
1,775,683.2510
Basic EPS
2.30
--
2.10
2.04
1.90
Diluted EPS
2.30
--
2.10
2.04
1.90
Basic Average Shares
910,546.6010
--
930,309.9210
935,984.1610
934,570.1320
Diluted Average Shares
910,546.6010
--
930,309.9210
935,984.1610
934,570.1320
Total Operating Income as Reported
2,954,438.1660
2,844,400.2613
2,415,108.4899
2,350,555.6177
2,266,989.9948
Total Expenses
8,802,655.2953
8,982,214.6779
9,999,326.2665
10,395,175.3119
9,876,231.9792
Net Income from Continuing & Discontinued Operation
2,089,979.9261
2,061,095.8040
1,953,650.8333
1,909,407.6879
1,775,683.2510
Normalized Income
2,223,756.9695
2,191,671.7495
2,232,037.2576
2,074,001.7284
1,845,367.0688
Interest Income
243,194.1661
247,956.6370
368,159.1204
315,137.4877
162,189.9690
Interest Expense
80,702.9482
88,606.5608
102,085.9231
97,545.9339
83,997.2346
Net Interest Income
156,477.6431
154,945.5978
261,270.2564
212,078.9190
74,323.0827
EBIT
3,000,997.7015
2,894,752.8284
2,484,752.4694
2,428,096.5441
2,329,686.0644
EBITDA
3,000,997.7015
3,469,888.9357
3,325,076.1011
3,080,420.5884
2,774,957.3727
Reconciled Cost of Revenue
4,049,948.2307
4,081,106.9569
4,465,473.3611
4,461,283.0761
4,253,087.4844
Reconciled Depreciation
--
575,136.1073
840,323.6318
652,324.0443
445,271.3083
Net Income from Continuing Operation Net Minority Interest
2,089,979.9261
2,061,095.8040
1,953,650.8333
1,909,407.6879
1,775,683.2510
Total Unusual Items Excluding Goodwill
-163,319.6331
-159,000.9090
-349,547.6740
-196,154.2125
-80,163.9658
Total Unusual Items
-163,319.6331
-159,000.9090
-349,547.6740
-196,154.2125
-80,163.9658
Normalized EBITDA
3,164,317.3346
3,628,889.8447
3,674,623.7751
3,276,574.8009
2,855,121.3384
Tax Rate for Calcs
0.0002
0.0002
0.0002
0.0002
0.0001
Tax Effect of Unusual Items
-29,542.5897
-28,424.9635
-71,161.2498
-31,560.1720
-10,480.1480
12/31/2021 - 6/29/2018
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade